SCHEMBL14670982

SCHEMBL14670982

CC(=O)N1CCC2(CC1)CC(C(C)C)C2

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.45
ALDH1A1 P00352 6/20 0.45
CYP2C19 P33261 4/20 0.45
MAPK1 P28482 2/20 0.45
KDM4E B2RXH2 1/20 0.44
CYP2D6 P10635 6/20 0.43
CYP2C9 P11712 5/20 0.43
USP2 O75604 6/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 3/20 0.41
HPGD P15428 5/20 0.40
HSD17B10 Q99714 4/20 0.40
HIF1A Q16665 2/20 0.40
PIK3CD O00329 1/20 0.39
CYP1A2 P05177 3/20 0.39
ALOX12 P18054 1/20 0.39
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18256186 0.89 CYP3A4 (0.43) CYP3A4ALDH1A1CYP2C19MAPK1KDM4E
SCHEMBL24574461 0.88 CYP2C9 (0.40) CYP3A4ALDH1A1CYP2C19MAPK1KDM4E
SCHEMBL26501046 0.84 CHRNB2 (0.38) CYP3A4ALDH1A1CYP2C19CYP2D6CYP2C9
SCHEMBL27061641 0.82 CYP3A4 (0.38) CYP3A4ALDH1A1CYP2C19MAPK1CYP2D6
SCHEMBL24007479 0.81 SMN1; SMN2 (0.44) CYP3A4ALDH1A1CYP2C19MAPK1KDM4E
SCHEMBL14670983 0.81 CYP2C9 (0.58) CYP3A4ALDH1A1CYP2C19MAPK1CYP2D6
SCHEMBL26518124 0.80 CYP3A4 (0.32) CYP3A4ALDH1A1CYP2C19MAPK1
SCHEMBL18256134 0.80 CYP2D6 (0.49) CYP3A4ALDH1A1CYP2C19CYP2D6CYP2C9
SCHEMBL16375283 0.80 KMT2A (0.40) CYP2C9KMT2ACYP1A2
SCHEMBL25157343 0.79 EPHX2 (0.43) CYP3A4ALDH1A1CYP2C19MAPK1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827639-B2 TDO2 and IDO1 inhibitors GENENTECH, INC. (US) 2023-11-28 US disclosed
US-20210332064-A1 ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER GENENTECH, INC. (US) 2021-10-28 US disclosed
US-20200108075-A1 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-04-09 US disclosed
US-9226923-B2 Spirocyclic molecules as protein kinase inhibitors NANJING ALLGEN PHARMA CO. LTD. (CN) 2016-01-05 US disclosed
US-20140243303-A1 SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS BETA PHARMA CANADA INC. (CA) 2014-08-28 US disclosed
WO-2013013308-A1 SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS BETA PHARMA CANADA INC. (CA) 2013-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827639-B2 TDO2 and IDO1 inhibitors IDO1, TDO2, IDO2 CYP3A4 428/4885ALDH1A1 808/4885CYP2C19 560/4885
US-20140243303-A1 SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS MET, RET, ALK CYP3A4 3514/4885ALDH1A1 571/4885CYP2C19 2538/4885
US-20200108075-A1 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF PHKG1, MAP4K5, HIPK1 CYP3A4 3884/4885ALDH1A1 3407/4885CYP2C19 4182/4885
US-20210332064-A1 ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER PGK1, PHKG1, NEK1 CYP3A4 2927/4885ALDH1A1 3038/4885CYP2C19 3575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.